Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Net Income (2016 - 2025)

Historic Net Income for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$23.1 million.

  • Ascendis Pharma A's Net Income rose 4043.14% to -$23.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$218.5 million, marking a year-over-year increase of 4532.67%. This contributed to the annual value of -$222.9 million for FY2025, which is 4337.04% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Net Income of -$23.1 million as of Q4 2025, which was up 4043.14% from -$62.8 million recorded in Q3 2025.
  • Ascendis Pharma A's Net Income's 5-year high stood at -$23.1 million during Q4 2025, with a 5-year trough of -$200.7 million in Q4 2022.
  • Over the past 5 years, Ascendis Pharma A's median Net Income value was -$112.0 million (recorded in 2024), while the average stood at -$108.9 million.
  • In the last 5 years, Ascendis Pharma A's Net Income crashed by 8524.76% in 2022 and then surged by 6993.03% in 2025.
  • Ascendis Pharma A's Net Income (Quarter) stood at -$121.3 million in 2021, then plummeted by 65.42% to -$200.7 million in 2022, then surged by 59.64% to -$81.0 million in 2023, then soared by 52.12% to -$38.8 million in 2024, then surged by 40.43% to -$23.1 million in 2025.
  • Its Net Income stands at -$23.1 million for Q4 2025, versus -$62.8 million for Q3 2025 and -$35.3 million for Q2 2025.